Sun Pharma to acquire Organon’s global biosimilars for $11.75B

Sun Pharma to acquire Organon’s global biosimilars business for $11.75 billion in cash. This all-cash deal marks one of India’s largest pharma acquisitions, significantly expanding Sun Pharma’s footprint in high-growth biosimilar markets. The acquisition includes 12 commercialized biosimilar products and a rich pipeline of 10+ candidates. The move strengthens India’s global pharma leadership amid rising demand for affordable biologics.

📊 STOCKS: SUNPHARMA | 🏢 SECTOR: Pharma | #HIGHIMPACT #Acquisition